Latest news with #SPECT
Hamilton Spectator
21-05-2025
- Business
- Hamilton Spectator
Curium and NRG PALLAS extend collaboration in the supply of essential medical isotope to hospitals
PETTEN, The Netherlands, May 21, 2025 (GLOBE NEWSWIRE) — NRG PALLAS and Curium have extended their collaboration to produce molybdenum-99 through a new multi-year agreement. Molybdenum-99, which transforms into technetium-99, is a critical isotope used in nuclear medicine. This agreement underlines the shared dedication of both partners to a stable and uninterrupted supply of technetium-99m for patient care worldwide. More Than 50 Million Diagnosis Annually Technetium-99m is used for hospitals and patients. More than 50 million nuclear medicine procedures are performed each year, with technetium-99m used in more than 80% of these diagnosis. The multi-year agreement between NRG PALLAS and Curium is essential to ensure the continuity of medical isotope supply. Peter Luijten, CEO NRG PALLAS, said 'These isotopes are important for both doctors and patients. The demand for technetium-99m remains strong and our close collaboration with Curium ensures hospitals will continue to be supplied with this isotope for years to come.' Frank de Lange, General Manager of Curium Netherlands, said 'The stable, global supply of medical isotopes to patients with specific health conditions is critical for accurate diagnosis before the treatment cycle of the patient begins. This partnership guarantees that supply.' About technetium-99m from molybdenum-99 Patients undergoing a SPECT scan in hospitals with indications such as cardiovascular diseases or various cancers receive an injection of a tracer—a radioactive substance. The radioactive component, technetium-99m, is derived from the molybdenum-99 manufactured by Curium from low-enriched uranium irradiated by NRG PALLAS. The irradiation process to produce molybdenum-99currently takes place in the High Flux Reactor (HFR) in Petten, the Netherlands, which operates around 260 days per year. As planned, this role will be taken over by the PALLAS-reactor, expected to be operational from 2030 onwards, which will offer an extended operational window of approximately 300 days per year. NRG PALLAS has implemented an extensive Long Term Safe Operation program for the HFR to maintain the safety and reliability of the reactor until the transition of irradiations to the PALLAS-reactor. About Curium Pharma Curium is a world leader in nuclear medicine with global headquarters in Paris, France. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for cancer and other debilitating conditions to over 14 million patients annually. The name 'Curium' honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit For more information: communications@ About NRG PALLAS NRG PALLAS is a Global Leader in Research on New Nuclear Technologies. Using the High Flux Reactor (HFR), NRG PALLAS produces medical isotopes that enable doctors worldwide to diagnose and treat diseases. Every day, 30,000 patients rely on medical isotopes from the Netherlands. To ensure future supply security, preparations are underway for the construction of the PALLAS-reactor. For more information: NRG PALLAS | Bram de Groot | Tel: +31 (0)6 42231102 | e-mail: | | LinkedIn NRG PALLAS
Yahoo
09-05-2025
- Business
- Yahoo
LNTH Q1 Earnings Call: Lantheus Lowers Outlook Amid Product Shifts and Divestitures
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) missed Wall Street's revenue expectations in Q1 CY2025, with sales flat year on year at $372.8 million. The company's full-year revenue guidance of $1.57 billion at the midpoint came in 1.8% below analysts' estimates. Its non-GAAP profit of $1.53 per share was 7.5% below analysts' consensus estimates. Is now the time to buy LNTH? Find out in our full research report (it's free). Revenue: $372.8 million vs analyst estimates of $378.8 million (flat year on year, 1.6% miss) Adjusted EPS: $1.53 vs analyst expectations of $1.65 (7.5% miss) Adjusted EBITDA: $149.6 million vs analyst estimates of $172.9 million (40.1% margin, 13.4% miss) The company dropped its revenue guidance for the full year to $1.57 billion at the midpoint from $1.58 billion, a 0.6% decrease Management lowered its full-year Adjusted EPS guidance to $6.65 at the midpoint, a 6.3% decrease Operating Margin: 27.4%, down from 28.8% in the same quarter last year Free Cash Flow Margin: 26.5%, down from 32.2% in the same quarter last year Market Capitalization: $5.57 billion Lantheus Holdings' first quarter results were driven by a combination of steady performance from its core imaging agents and significant business transformation initiatives. Management attributed the quarter's results to the impact of contracting strategies in its radiopharmaceutical segment, ongoing competitive dynamics in its PYLARIFY product, and the divestiture of its SPECT business. CEO Brian Markison emphasized, 'We are laying the foundation for the next chapter of our business,' highlighting the importance of recent acquisitions and a focus on PET radiodiagnostics and radiotherapeutics. Looking ahead, Lantheus' downward adjustment of full-year guidance was shaped by a more cautious view on PYLARIFY's growth trajectory and anticipated integration costs from new acquisitions. Management remains focused on streamlining its portfolio, expanding its Alzheimer's disease diagnostics via the Life Molecular Imaging acquisition, and investing in early- and late-stage pipeline assets. Markison noted that these moves are designed to 'diversify our revenue streams and unlock additional value,' though leadership acknowledged ongoing headwinds in reimbursement and market competition. Lantheus' leadership pointed to ongoing portfolio realignment and competitive pressure as key influences on first quarter outcomes. The company's business update centered around the strategic sale of its SPECT business, acquisitions targeting growth in PET imaging, and the positioning of its pipeline for future expansion. Portfolio transformation underway: Management is actively shifting away from legacy SPECT imaging, opting to divest this segment to SHINE Technologies. This streamlining move is intended to focus the company on higher-margin PET diagnostics and radiotherapeutics. Acquisition-driven pipeline expansion: The completed Evergreen Theragnostics acquisition and pending Life Molecular Imaging (LMI) deal are expected to add commercial products and expand the pipeline, particularly in neuroendocrine tumor imaging and Alzheimer's diagnostics. Evergreen brings manufacturing capabilities and a pipeline that includes OCTEVY, while LMI adds NEURACEQ, a PET imaging agent for Alzheimer's disease. PYLARIFY market dynamics: PYLARIFY, Lantheus' PSMA PET imaging agent, saw continued volume growth offset by a low-single-digit decline in net price. Management cited increased competitive disruption among smaller, non-contracted imaging centers due to reimbursement changes, but believes expanded contracting and product availability will help regain momentum. Alzheimer's diagnostics opportunity: The company anticipates significant growth in the Alzheimer's PET imaging market, citing over 100 therapeutic candidates in development. Management expects its combined Alzheimer's diagnostics platform to be positioned for leadership as the market expands. Margin pressures and cost allocation: Operating margins declined in part due to increased R&D spend supporting a broader pipeline and non-recurring transaction expenses. The company expects divesting lower-margin businesses and integrating acquisitions to support future margin improvement. Management's outlook for the remainder of the year is shaped by the integration of new acquisitions, ongoing reimbursement headwinds in core imaging agents, and anticipated growth in the Alzheimer's diagnostics market. Integration of new acquisitions: Lantheus expects the addition of Evergreen and LMI to diversify its revenue base and provide new growth avenues, though near-term earnings will be diluted by integration costs and increased R&D investment. Reimbursement environment and competition: Ongoing changes in Medicare reimbursement and heightened competition, especially for PYLARIFY, are expected to impact near-term growth and pricing power. Management is focused on expanding contracting efforts to smaller imaging centers to mitigate these effects. Alzheimer's diagnostics and pipeline launches: The company believes growth in Alzheimer's disease PET imaging will accelerate with the launch of new diagnostic agents and continued development of therapeutic partnerships, positioning Lantheus to benefit from increasing demand in this area. Anthony Petrone (Mizuho Financial Group): Asked about PYLARIFY's competitive dynamics and the rationale for divesting the SPECT business; management described short-term disruptions among smaller centers and emphasized a focus on growth platforms. Roanna Ruiz (Leerink Partners): Queried about drivers for the narrowed guidance range and how resources from the SPECT sale would be redeployed; management cited more cautious PYLARIFY assumptions and a focus on PET diagnostics and radiotherapeutics. Richard Newitter (Truist Securities): Sought clarity on expected dilution from acquisitions and whether double-digit revenue growth in 2026 remains likely; management reiterated low-single-digit dilution and stated that double-digit growth is still anticipated with full-year contributions from acquisitions. Matt Taylor (Jefferies): Asked how the acquisitions would affect growth rates in 2026 and beyond; management pointed to launches of OCTEVY, PNT2003, and Alzheimer's agents as potential drivers for sustained double-digit growth. Paul Choi (Goldman Sachs): Inquired about PYLARIFY pricing trends and the outlook for Alzheimer's PET scan market growth post-acquisition; leadership highlighted ongoing payer discussions and robust growth in Alzheimer's imaging claims. In future quarters, the StockStory team will watch (1) the pace and success of Evergreen and Life Molecular Imaging integration, (2) stabilization and potential recovery in PYLARIFY's pricing and volume trends as new contracting strategies are implemented, and (3) early signs of expansion in the Alzheimer's PET imaging segment following NEURACEQ's addition. The timing of key regulatory filings and product launches will also be critical markers for the company's evolving growth trajectory. Lantheus currently trades at a forward P/E ratio of 11.2×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
Yahoo
27-01-2025
- Business
- Yahoo
Telix Completes Acquisition of RLS (USA) Inc.
MELBOURNE, Australia and INDIANAPOLIS, Jan. 28, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET[1], SPECT[2] and therapeutic radiopharmaceuticals. The acquisition immediately enhances Telix's presence in the United States (U.S.), with a network of over 30 radiopharmacies[3] dispensing radiopharmaceuticals manufactured by Telix and other companies, while bringing a team of highly-skilled and multi-disciplinary radiopharmaceutical professionals into the Company. The acquisition is part of Telix's strategy to establish an integrated radiopharmaceutical ecosystem, enhancing its ability to deliver novel therapeutic and diagnostic radiopharmaceuticals to patients. The RLS footprint of over 100,000 square ft of appropriately licensed expansion space provides the opportunity to build a next-generation radiometal production network to benefit Telix, select commercial partners, and patients. RLS will continue to operate under the same name and as a standalone business within Telix Manufacturing Solutions (TMS), which includes other key Telix brands with multi-vendor and third-party relationships such as ARTMS, IsoTherapeutics and Optimal Tracers. The addition of RLS's operations will significantly strengthen Telix's commercial infrastructure and distribution capabilities in its largest market, including the capacity to undertake in-house cyclotron manufacturing powered by Telix's ARTMS QUANTM Irradiation System™ (QIS™) cyclotron technology, enabling standardized, high-efficiency and cost-effective production of radiometals. Dr. Christian Behrenbruch, Telix Managing Director and Group Chief Executive Officer, said, "We are pleased to officially welcome the RLS team to Telix. The completion of this acquisition marks a milestone in our journey to become the leader in radiopharmaceuticals, as the RLS network significantly boosts our existing in-house and partner capabilities. With RLS's distribution and operational expertise, Telix is strongly positioned to bring our growing portfolio of innovative products to more patients across the U.S." Stephen Belcher, RLS Chief Executive Officer, added, "The RLS team is delighted to be joining Telix, as we combine our 40-year history in radiopharmaceuticals with Telix's growing investment in its North American footprint. Together we can accelerate the availability of transformative radiopharmaceuticals and build on our respective commitments to innovative patient care. We are excited to be part of the Telix story going forward." Acquisition Details Under the previously disclosed terms of the transaction[4], Telix has acquired 100% ownership of RLS (USA) Inc. The purchase price comprised of upfront cash consideration of US$230 million before adjustments for cash and cash equivalents (net of restricted cash); debt and debt equivalents; transaction expenses; and working capital, and deferred cash consideration up to a maximum of US$20 million, contingent on achievement of certain milestones related to demonstration of accretive financial and operational performance during the four-quarters following closing. The acquisition and related transaction costs were funded from existing cash reserves. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Telix's lead prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[5], by the Australian Therapeutic Goods Administration (TGA)[6], and by Health Canada[7]. Telix has received a positive decision on its Marketing Authorization Application (MAA) for Illuccix submitted in Europe[8]. Telix's osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix's miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is approved in the U.S., having been registered with the FDA and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area for the intra-operative detection of sentinel lymph nodes (SLNs). No other Telix product has received a marketing authorization in any jurisdiction. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the anticipated benefits of Telix's acquisition of RLS; the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. [1] Positron emission tomography. [2] Single-photon emission computed tomography. [3] In January 2025, RLS completed the acquisition of Advanced Isotopes of Nevada, a Las Vegas-based radiopharmacy, now operating under Las Vegas Radiopharmacy Inc., a wholly-owned subsidiary of RLS. [4] Telix ASX disclosure 23 September 2024. [5] Telix ASX disclosure 20 December 2021. [6] Telix ASX disclosure 2 November 2021. [7] Telix ASX disclosure 14 October 2022. [8] Telix ASX disclosure 17 January 2025. View original content to download multimedia: SOURCE Telix Pharmaceuticals Limited Sign in to access your portfolio
